amivantamab + tepotinib

This combination therapy consists of amivantamab, a bispecific monoclonal antibody, and tepotinib, a small molecule tyrosine kinase inhibitor. Amivantamab targets both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET) receptor, while tepotinib is a highly selective MET inhibitor. The combination is primarily being investigated in clinical trials sponsored by the M.D. Anderson Cancer Center for the treatment of patients with non-small cell lung cancer (NSCLC) harboring MET alterations, such as MET exon 14 skipping mutations or MET amplification. By simultaneously targeting EGFR and MET through multiple mechanisms, this regimen aims to provide more robust inhibition of oncogenic signaling and overcome potential resistance mechanisms in MET-driven lung cancers.

Brand names

Rybrevant + Tepmetko

Other names

amivantamab and tepotinib combinationamivantamab and tepotinib combination in MET-altered NSCLC